充血性心力衰竭患者心房颤动的管理进展
Advances in the management of atrial fibrillation in congestive heart failure.
作者信息
Gopinathannair Rakesh, Olshansky Brian
机构信息
Division of Cardiovascular Medicine, University of Iowa Hospitals and Clinics Iowa City, IA 52242 USA.
出版信息
F1000 Med Rep. 2009 Jan 21;1:4. doi: 10.3410/M1-4.
Abstract
Atrial fibrillation, a common problem in patients with heart failure, is associated with increased mortality and morbidity. Pharmacological as well as invasive management and the endpoints of such management are complex. Recent randomized trials indicate that a rate-control strategy, along with anticoagulation treatment with warfarin, when appropriate, has a similar outcome in terms of mortality and morbidity as rhythm control, and could, therefore, be considered as the primary management strategy for atrial fibrillation in patients with heart failure.
摘要
心房颤动是心力衰竭患者的常见问题，与死亡率和发病率增加相关。药物治疗以及侵入性治疗及其治疗终点都很复杂。近期的随机试验表明，心率控制策略，以及在适当情况下使用华法林进行抗凝治疗，在死亡率和发病率方面与节律控制具有相似的结果，因此可被视为心力衰竭患者心房颤动的主要治疗策略。
相似文献
1
Advances in the management of atrial fibrillation in congestive heart failure.充血性心力衰竭患者心房颤动的管理进展
F1000 Med Rep. 2009 Jan 21;1:4. doi: 10.3410/M1-4.
2
The RACE study in perspective of randomized studies on management of persistent atrial fibrillation.从持续性心房颤动管理的随机研究角度看RACE研究
Card Electrophysiol Rev. 2003 Jun;7(2):118-21. doi: 10.1023/a:1027439430017.
3
[Atrial fibrillation in heart failure].[心力衰竭中的心房颤动]
Herz. 2002 Jun;27(4):378-87. doi: 10.1007/s00059-002-2399-y.
4
AFFIRM and RACE trials: implications for the management of atrial fibrillation.AFFIRM和RACE试验：对心房颤动管理的启示
Card Electrophysiol Rev. 2003 Dec;7(4):366-9. doi: 10.1023/B:CEPR.0000023140.38226.75.
5
Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians.新发现心房颤动的管理：美国家庭医师学会和美国医师学会的临床实践指南
Ann Intern Med. 2003 Dec 16;139(12):1009-17. doi: 10.7326/0003-4819-139-12-200312160-00011.
6
Rationale for the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial.心房颤动与充血性心力衰竭（AF-CHF）试验的原理。
Card Electrophysiol Rev. 2003 Sep;7(3):208-10. doi: 10.1023/B:CEPR.0000012383.63580.c8.
7
Atrial fibrillation and congestive heart failure.心房颤动与充血性心力衰竭
Curr Opin Cardiol. 2009 Jan;24(1):29-34. doi: 10.1097/hco.0b013e32831c8c58.
8
Atrial fibrillation and heart failure comorbidity.心房颤动与心力衰竭合并症。
Minerva Cardioangiol. 2005 Aug;53(4):299-311.
9
Rate control is a better initial treatment for patients with atrial fibrillation and heart failure--rhythm control vs. rate control: which is better in the management of atrial fibrillation? (Rate-side).心率控制是房颤伴心力衰竭患者的更佳初始治疗方法——节律控制与心率控制：在房颤管理中哪个更好？（Rate-side）。
Circ J. 2011;75(4):970-8. doi: 10.1253/circj.cj-11-0080. Epub 2011 Mar 11.
10
Rate control in atrial fibrillation: choice of treatment and assessment of efficacy.心房颤动的心率控制：治疗选择与疗效评估
Drugs. 2003;63(14):1489-509. doi: 10.2165/00003495-200363140-00005.
本文引用的文献
1
Statins and prevention of atrial fibrillation in patients with heart failure.他汀类药物与心力衰竭患者心房颤动的预防。
Int J Cardiol. 2009 Jul 10;135(3):e83-4. doi: 10.1016/j.ijcard.2008.04.042. Epub 2008 Jul 14.
2
Increased mortality after dronedarone therapy for severe heart failure.决奈达隆治疗严重心力衰竭后死亡率增加。
N Engl J Med. 2008 Jun 19;358(25):2678-87. doi: 10.1056/NEJMoa0800456.
3
Rhythm control versus rate control for atrial fibrillation and heart failure.心房颤动与心力衰竭的节律控制与率控制
N Engl J Med. 2008 Jun 19;358(25):2667-77. doi: 10.1056/NEJMoa0708789.
4
Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling.ω-3多不饱和脂肪酸可预防与心力衰竭相关的心房颤动，但不能预防心房心动过速重构。
Circulation. 2007 Nov 6;116(19):2101-9. doi: 10.1161/CIRCULATIONAHA.107.704759. Epub 2007 Oct 22.
5
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).在非瓣膜性心房颤动患者中，达比加群联合或不联合阿司匹林与单独使用华法林的比较（PETRO研究）
Am J Cardiol. 2007 Nov 1;100(9):1419-26. doi: 10.1016/j.amjcard.2007.06.034. Epub 2007 Aug 17.
6
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.伴有和不伴有左心室收缩功能障碍的慢性心力衰竭患者的心房颤动及临床事件风险：坎地沙坦治疗心力衰竭降低死亡率和发病率评估（CHARM）项目的结果
J Am Coll Cardiol. 2006 May 16;47(10):1997-2004. doi: 10.1016/j.jacc.2006.01.060. Epub 2006 Apr 27.
7
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂预防心房颤动：一项荟萃分析。
J Am Coll Cardiol. 2005 Jun 7;45(11):1832-9. doi: 10.1016/j.jacc.2004.11.070.
8
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.胺碘酮或植入式心脏复律除颤器用于治疗充血性心力衰竭。
N Engl J Med. 2005 Jan 20;352(3):225-37. doi: 10.1056/NEJMoa043399.
9
Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study.非瓣膜性持续性心房颤动患者的心率控制与节律控制：波兰如何治疗慢性心房颤动（HOT CAFE）研究结果
Chest. 2004 Aug;126(2):476-86. doi: 10.1378/chest.126.2.476.
10
The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation.心房颤动节律管理后续调查（AFFIRM）研究：心房颤动的心率控制方法
J Am Coll Cardiol. 2004 Apr 7;43(7):1201-8. doi: 10.1016/j.jacc.2003.11.032.
Zotero 插件